134 related articles for article (PubMed ID: 15764408)
21. Evidence for a role of cytochrome P450 2D6 and 3A4 in ethylmorphine metabolism.
Liu Z; Mortimer O; Smith CA; Wolf CR; Rane A
Br J Clin Pharmacol; 1995 Jan; 39(1):77-80. PubMed ID: 7756104
[TBL] [Abstract][Full Text] [Related]
22. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
Yu A; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
[TBL] [Abstract][Full Text] [Related]
23. Metabolism of 7-benzyloxy-4-trifluoromethyl-coumarin by human hepatic cytochrome P450 isoforms.
Renwick AB; Surry D; Price RJ; Lake BG; Evans DC
Xenobiotica; 2000 Oct; 30(10):955-69. PubMed ID: 11315104
[TBL] [Abstract][Full Text] [Related]
24. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE.
Kubo M; Koue T; Inaba A; Takeda H; Maune H; Fukuda T; Azuma J
Drug Metab Pharmacokinet; 2005 Feb; 20(1):55-64. PubMed ID: 15770075
[TBL] [Abstract][Full Text] [Related]
25. Cytochrome b5 is a major determinant of human cytochrome P450 CYP2D6 and CYP3A4 activity in vivo.
Henderson CJ; McLaughlin LA; Scheer N; Stanley LA; Wolf CR
Mol Pharmacol; 2015 Apr; 87(4):733-9. PubMed ID: 25657337
[TBL] [Abstract][Full Text] [Related]
26. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
27. Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro-In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound.
T'jollyn H; Snoeys J; Van Bocxlaer J; De Bock L; Annaert P; Van Peer A; Allegaert K; Mannens G; Vermeulen A; Boussery K
Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):537-543. PubMed ID: 27317395
[TBL] [Abstract][Full Text] [Related]
28. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes.
Staack RF; Paul LD; Springer D; Kraemer T; Maurer HH
Biochem Pharmacol; 2004 Jan; 67(2):235-44. PubMed ID: 14698036
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in elderly hospital patients after single and multiple doses of distalgesic. Preliminary analysis of results.
Crome P; Gain R; Ghurye R; Flanagan RJ
Hum Toxicol; 1984 Aug; 3 Suppl():41S-48S. PubMed ID: 6480016
[TBL] [Abstract][Full Text] [Related]
30. Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan.
McCune JS; Lindley C; Decker JL; Williamson KM; Meadowcroft AM; Graff D; Sawyer WT; Blough DK; Pieper JA
J Clin Pharmacol; 2001 Jul; 41(7):723-31. PubMed ID: 11452704
[TBL] [Abstract][Full Text] [Related]
31. Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes.
Tang L; Ye L; Lv C; Zheng Z; Gong Y; Liu Z
Toxicol Lett; 2011 Apr; 202(1):47-54. PubMed ID: 21277363
[TBL] [Abstract][Full Text] [Related]
32. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
33. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450.
Ring BJ; Gillespie JS; Binkley SN; Campanale KM; Wrighton SA
Drug Metab Dispos; 2002 Sep; 30(9):957-61. PubMed ID: 12167559
[TBL] [Abstract][Full Text] [Related]
34. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline.
Davies BJ; Herbert MK; Coller JK; Somogyi AA; Milne RW; Sallustio BC
Br J Clin Pharmacol; 2008 Mar; 65(3):347-54. PubMed ID: 17875193
[TBL] [Abstract][Full Text] [Related]
35. Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4.
Renwick AB; Lewis DF; Fulford S; Surry D; Williams B; Worboys PD; Cai X; Wang RW; Price RJ; Lake BG; Evans DC
Xenobiotica; 2001 Apr; 31(4):187-204. PubMed ID: 11465405
[TBL] [Abstract][Full Text] [Related]
36. CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes.
Davies BJ; Coller JK; Somogyi AA; Milne RW; Sallustio BC
Drug Metab Dispos; 2007 Jan; 35(1):128-38. PubMed ID: 17050648
[TBL] [Abstract][Full Text] [Related]
37. Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Han SY; Zhao HY; Zhou N; Zhou F; Li PP
J Ethnopharmacol; 2014; 151(1):210-7. PubMed ID: 24157377
[TBL] [Abstract][Full Text] [Related]
38. In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron.
Firkusny L; Kroemer HK; Eichelbaum M
Biochem Pharmacol; 1995 Jun; 49(12):1777-84. PubMed ID: 7598739
[TBL] [Abstract][Full Text] [Related]
39. Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.
Funck-Brentano C; Boëlle PY; Verstuyft C; Bornert C; Becquemont L; Poirier JM
Eur J Clin Pharmacol; 2005 Dec; 61(11):821-9. PubMed ID: 16315033
[TBL] [Abstract][Full Text] [Related]
40. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol.
Pan L; Belpaire FM
Eur J Clin Pharmacol; 1999 Oct; 55(8):599-604. PubMed ID: 10541779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
